Torpharm ANDA
This article was originally published in The Tan Sheet
Executive Summary
Private labeler's famotidine 10 mg tablets (J&J/Merck's Pepcid AC) approved by FDA March 12. ANDA (75-610) marks fifth private label approval for the H2 antagonist, behind Ivax, Teva (licensed by Perrigo), Dr. Reddy's Labs (licensed by Leiner), Genpharm (1"The Tan Sheet" Jan. 7, 2002, In Brief)...
You may also be interested in...
Eon Labs famotidine
Firm's application (ANDA 76-101) for generic equivalent to J&J/Merck's Pepcid AC approved by FDA Oct. 21. Eon likely will partner with another company to bring the H2 antagonist to market but has no imminent launch plans. Five other companies hold ANDA approval for 10 mg tablets (1"The Tan Sheet" April 8, 2002, In Brief)...
Famotidine, permethrin lotion ANDAs
Genpharm receives FDA clearance for famotidine 10 mg tablets (ANDA 75-674) Dec. 21, becoming fourth firm to gain approval for private label stomach remedy equivalent to J&J/Merck's Pepcid AC (1"The Tan Sheet" Aug. 27, 2001, In Brief). Clay-Park Labs' Permethrin Lotion 1% (ANDA 76-090) receives FDA approval Dec. 20 and is second generic version of Pfizer/Warner-Lambert's Nix pediculicide...
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.